Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

HPC Offered for PRESERVE Expansion

NCT ID: NCT07145411Sponsor: Ossium Health, Inc.Last updated: 2025-08-28

Summary

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Arms & interventions

  • OtherBone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)

    The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.

Outcome measures

Primary

  • Neutrophil engraftment

    1\. To determine cumulative incidences of neutrophil engraftment (ANC ≥500/µL for 3 consecutive values)

    Time frame: 28 days

Eligibility criteria

Sex: AllAge: 12 Years to 80 YearsHealthy volunteers: No
Inclusion Criteria: Patients aged 12-80 may be eligible\* to receive bone marrow for transplantation through the Ossium HOPE Program if: Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks

Study locations (4)

University of Alabama, Birmingham

Birmingham, Alabama, 35294

Recruiting
Mary Underwood · Contact

Henry Ford Health

Detroit, Michigan, 48202

Recruiting
Kelly Walls · Contact

The Ohio State University Medical Center

Columbus, Ohio, 43210

Recruiting
Nicole Szuminski · Contact

Tristar Centennial Medical Center

Nashville, Tennessee, 37203

Recruiting
Angela Heine · Contact
HPC Offered for PRESERVE Expansion | Cancerify